Table 1.
Baseline characteristics of AAP-treated and ENZ-treated patients
| AAP (n=46) | ENZ (n=59) | P values | |
| Age, years, median (range) | n=46 73 (53–90) |
n=59 76 (60–92) |
0.083 |
| LDH at baseline, IU/L, median (range) | n=21 226.00 (130–1207) |
n=20 229.50 (170–837) |
0.755 |
| ALP at baseline, IU/L, median (range) | n=37 94.00 (34–2435) |
n=46 91.00 (47–4344) |
0.781 |
| PSA at baseline, ng/mL, median (range) | n=46 15.56 (1.1–588) |
n=59 36.00 (1.3–450) |
0.605 |
| Gleason score at initial diagnosis, n (%) | 0.944 | ||
| ≤7 | 24 (52.2) | 29 (49.2) | |
| ≥8 | 18 (39.1) | 25 (42.4) | |
| Missing | 4 (8.7) | 5 (8.5) | |
| ECOG performance score, n (%) | 0.627 | ||
| 0/1 | 41 (89.1) | 49 (83.1) | |
| ≥2 | 4 (8.7) | 7 (11.9) | |
| Missing | 1 (2.2) | 3 (5.1) | |
| Any visceral metastases, n (%) | 0.646 | ||
| No | 40 (87.0) | 53 (89.8) | |
| Yes | 6 (13.0) | 6 (10.2) | |
| Anaemia, n (%) | 0.810 | ||
| Grade ≤2 | 39 (84.8) | 51 (86.4) | |
| Grade ≥3 | 0 (0.0) | 0 (0.0) | |
| Missing | 7 (15.2) | 8 (13.6) | |
| Opioid use at baseline, n (%) | 0.694 | ||
| No | 36 (78.3) | 48 (81.4) | |
| Yes | 10 (21.7) | 11 (18.6) | |
| Sedative use at baseline, n (%) | 0.281 | ||
| No | 39 (84.8) | 54 (91.5) | |
| Yes | 7 (15.2) | 5 (8.5) |
AAP, abiraterone acetate plus prednisone; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group.; ENZ, enzalutamide; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.